Approvals

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
FDA
The U.S. Food and Drug Administration (FDA) approved another therapy for Duchenne muscular dystrophy (DMD), this time NS Pharma’s Viltepso (viltolarsen).
FDA
Olinvyk is indicated for short-term intravenous use in hospitals or other controlled clinical settings, such as during inpatient and outpatient procedures.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
FDA
Genentech, a Roche company, announced the U.S. Food and Drug Administration (FDA) had approved its Evrysdi (risdiplam) for spinal muscular atrophy (SMA) in adults and children two months of age and older.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
FDA
Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
FDA
Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
PRESS RELEASES